Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus

Matthew A. Tyler, Ilya V. Ulasov, Anton Borovjagin, Adam M. Sonabend, Andrey Khramtsov, Yu Han, Paul Dent, Paul B. Fisher, David T. Curiel, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Malignant brain tumors remain refractory to adenovirus type 5 (Ad5) - based gene therapy, mostly due to the lack of the primary Ad5 receptor, the coxsackie and adenovirus receptor, on brain tumor cells. To bypass the dependence on coxsackie and adenovirus receptor for adenoviral entry and infectivity, we used a novel, double targeted Ad5 backbone - based vector carrying a chimeric Ad5/3 fiber with integrin-binding RGD motif incorporated in its Ad3 knob domain. We then tested the new virus in vitro and in vivo in the setting of malignant glioma. Ad5/3-RGD showed a 10-fold increase in gene expression in passaged cell lines and up to 75-fold increase in primary tumors obtained from patients relative to the control. These results were further corroborated in our in vivo human glioma xenograft model, where the Ad5/3-RGD vector showed a 1,000-fold increase in infectivity as compared with the control. Taken together, our findings indicate that Ad5/3-RGD may be a superior vector for applications in glioma gene therapy and therefore warrants further attention in the field of neuro-oncology.

Original languageEnglish (US)
Pages (from-to)2408-2416
Number of pages9
JournalMolecular cancer therapeutics
Issue number9
StatePublished - Sep 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus'. Together they form a unique fingerprint.

Cite this